Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478666 | 0.93 | NPC1 (0.49) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL3471069 | 0.90 | TP53 (0.54) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL1594800 | 0.78 | GAA (0.61) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL15690853 | 0.77 | GAA (0.49) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL5232747 | 0.77 | GAA (0.47) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL1593778 | 0.73 | PTGES2 (0.67) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL3010846 | 0.73 | GAA (0.64) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL2633819 | 0.73 | GAA (0.67) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL3473539 | 0.71 | PTGES2 (0.65) | NPC1GAAL3MBTL1POLBPTGES2 | |
| SCHEMBL3472654 | 0.70 | PTGES2 (0.64) | NPC1GAAL3MBTL1POLBPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | NPC1 41/4885GAA 2305/4885L3MBTL1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.